Consensus or Controversy? Clinical Investigators Provide
Perspectives on the Current and Future Management of Prostate
Cancer — Part 1: Our one-on-one interview with Dr Antonarakis
featuring emerging research and cases from his practice.
Initial evaluation of prognostic indicators in
hormone-sensitive prostate cancer (HSPC) versus
castration-resistant prostate cancer (CRPC) (0:00)
Effect of prostate-specific antigen (PSA) doubling time on time
to metastasis and overall survival in nonmetastatic CRPC;
improvement in metastasis-free survival with androgen receptor
antagonist therapy (4:16)
Perspective on the use of intermittent androgen deprivation
therapy (ADT) for patients with nonmetastatic HSPC and rising PSA
levels (12:35)
Structural and mechanistic similarities and differences between
available (apalutamide, enzalutamide) and investigational
(darolutamide) androgen receptor antagonists (19:39)
Initial results of the Phase III ARAMIS trial: Metastasis-free
survival improvement and tolerability of darolutamide versus
placebo for nonmetastatic CRPC (22:41)
ARASENS: An ongoing Phase III trial evaluating darolutamide
versus placebo in combination with standard ADT and docetaxel for
patients with metastatic HSPC (25:38)
Perspective on the new drug application and potential FDA
approval of darolutamide for nonmetastatic CRPC (27:02)
Spectrum and frequency of systemic and CNS-related side effects
associated with apalutamide, enzalutamide and darolutamide
(28:29)
Updated analysis of progression-free survival with first
subsequent therapy (PFS2) in the SPARTAN study of apalutamide for
high-risk nonmetastatic CRPC (31:50)
ARCHES: Design, efficacy and tolerability results from a Phase
III trial of ADT with enzalutamide or placebo for metastatic HSPC
(36:22)
Selection and sequencing of therapy for patients with
metastatic prostate cancer (42:01)
Correlation between the presence of androgen receptor splice
variant 7 (AR-V7) and outcomes with secondary hormonal therapy and
chemotherapy in metastatic CRPC (45:58)
Prevalence and detection of AR-V7 in patients with metastatic
CRPC (50:48)
Overview of BRCA1/2 and other DNA repair gene mutations that
may confer sensitivity to PARP inhibition (54:32)
Efficacy and FDA breakthrough therapy designations for olaparib
and rucaparib for metastatic CRPC (58:49)
GALAHAD: Preliminary results of a Phase II trial of niraparib
for patients with metastatic CRPC and biallelic DNA repair gene
defects (1:1:10)
Response to PARP inhibitor therapy in patients with metastatic
CRPC with BRCA1/2 versus ATM mutations (1:4:06)
Activity of platinum-based chemotherapy in patients with
metastatic CRPC and germline BRCA mutations (1:7:29)
Clinical experience with PARP inhibitor-associated side effects
in men with metastatic CRPC (1:12:35)
Perspective on the negative results of the Phase III ERA 223
trial evaluating radium-223 dichloride in combination with
abiraterone acetate for patients with chemotherapy-naïve metastatic
CRPC and bone metastases (1:14:56)
Appropriate use of radium-223 for the treatment of symptomatic
metastatic CRPC (1:19:54)
Biologic rationale for and ongoing investigation of
lutetium-177-prostate-specific membrane antigen (PSMA)-617 for
progressive PSMA-positive metastatic CRPC (1:23:03)
KEYNOTE-199: Updated analysis of a Phase II trial of
pembrolizumab monotherapy for patients with metastatic CRPC
previously treated with docetaxel (1:27:39)
Initial results of the Phase II CheckMate 650 trial of
nivolumab with ipilimumab for metastatic CRPC (1:30:11)
Prevalence of microsatellite instability-high (MSI-H)/mismatch
repair-deficient (dMMR) molecular phenotype and response to immune
checkpoint blockade in patients with prostate cancer (1:35:02)
Emerging data with olaparib in combination with anti-PD-1/PD-L1
checkpoint blockade for metastatic CRPC (1:37:38)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.